Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Safety and efficacy of belimumab in systemic lupus erythematosus academic clinical practices
Journal of rheumatology, v 42(12), pp 2288-2295
01 Nov 2015
PMID: 26523030
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
<p>Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE).</p><p>Methods. Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician's impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems.</p><p>Results. Of 195 patients treated with belimumab at 10 academic centers, 96% were taking background medications for SLE at initiation of belimumab, with 74% taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51% responded clinically and 67% had >= 25% improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued corticosteroids.</p><p>Conclusion. Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.</p>
Metrics
Details
- Title
- Safety and efficacy of belimumab in systemic lupus erythematosus academic clinical practices
- Creators
- Joyce S. Hui-Yuen - New York Hospital QueensArthi ReddyJennifer TaylorXiaoqing LiAndrew H. EichenfieldLiza M. BermudezAmy J. StarrLisa F. ImundoJill BuyonRichard A. FurieDiane L. KamenSusan ManziMichelle PetriRosalind Ramsey-GoldmanRonald F. van VollenhovenDaniel J. WallaceAnca Askanase
- Publication Details
- Journal of rheumatology, v 42(12), pp 2288-2295
- Publisher
- J RHEUMATOL PUBL CO; TORONTO
- Number of pages
- 8
- Grant note
- GlaxoSmithKlineT32 Medical Genetics training grant from the US National Institutes of Health
Supported by an investigator-initiated award to the Systemic Lupus Erythematosus International Collaborating Clinics from GlaxoSmithKline. Dr. Hui-Yuen is the recipient of a T32 Medical Genetics training grant from the US National Institutes of Health. Dr. Askanase is a consultant for GlaxoSmithKline (< $10,000 in the past 12 months), and Dr. Petri has been a consultant for GlaxoSmithKline.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000365909900011
- Scopus ID
- 2-s2.0-84948799807
- Other Identifier
- 991021933903004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology